Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility
October 17, 2023 08:05 ET
|
Avid Bioservices, Inc
Avid completes construction of cell and gene theapy facility bringing total revenue generating capacity to up to ~$400 Million annually
Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023
August 31, 2023 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023
June 21, 2023 16:07 ET
|
Avid Bioservices, Inc
-- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Million in Net New Business Orders Resulting in a...
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023
June 14, 2023 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Participate in RBC Capital Markets Global Healthcare Conference
May 10, 2023 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers
April 04, 2023 08:05 ET
|
Avid Bioservices, Inc
Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility First Customer Project in Newly Expanded Capacity to Kick-Off This...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2022 and Recent Developments
December 06, 2022 16:05 ET
|
Avid Bioservices, Inc
-- Recorded Second Quarter Revenue of $34.8 Million -- -- Signed $26 Million in Net New Business Orders Resulting in a Backlog of $147 Million, an Increase of 23% Year-Over-Year -- -- Mammalian...
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022
November 29, 2022 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Appoints Oksana Lukash as Vice President, People
November 16, 2022 08:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to Participate in RBC Global CDMO Conference
September 27, 2022 16:05 ET
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...